ALTERATIONS IN ATC CLASSIFICATION/ valid from January 2017 sorted according to previous ATC code
Previous ATC code ATC level name New ATC code
A10BX04 exenatide A10BJ01
A10BX07 liraglutide A10BJ02
A10BX09 dapagliflozin A10BK01
A10BX10 lixisenatide A10BJ03
A10BX11 canagliflozin A10BK02
A10BX12 empagliflozin A10BK03
A10BX13 albiglutide A10BJ04
A10BX14 dulaglutide A10BJ05
B02BD09 nonacog alfa B02BD041)
B02BD12 trenonacog alfa B02BD041)
L01BA01 methotrexate L04AX032)
L04AC06 mepolizumab R03DX09
R05CB12 tiopronin G04BX16
1) Existing ATC code B02BD04 coagulation factor IX 2) Splitting of ATC code. Only the classification of pre-filled syringe/pen of methotrexate for use in non-cancer indications is changed. These products will be moved to the existing ATC code for oral administered product of methotrexate. Parenteral preparations used for treatment of cancer will remain in L01BA01.
WHO-Oslo, December 2016
Other alterations in ATC classification, i.e. new levels (this list includes only new levels assigned in connection with an alteration), deleted levels and altered names of ATC levels valid from January 2017 sorted according to ATC code
Previous ATC code and level name New ATC code and/or level name
A10BJ Glucagon-like peptide-1 (GLP-1) analogues
A10BK Sodium-glucose co-transporter 2 (SGLT2) inhibitors
C07FX Beta blocking agents, other combinations
N02AJ1 Opioids in combination with non-opioid analgesics C07AA57 sotalol, combinations C07FX02 sotalol and acetylsalicylic acid C07AB52 metoprolol, combinations C07FX03 metoprolol and acetylsalicylic acid C07AB57 bisoprolol, combinations C07FX04 bisoprolol and acetylsalicylic acid C07F Beta blocking agents and other C07F Beta blocking agents, other combinations antihypertensives C07FA Beta blocking agents, non-selective, and Deleted other antihypertensives C07FA05 propranolol and other antihypertensives C07FX01 propranolol and other combinations C07FB Beta blocking agents, selective, and other C07FB Beta blocking agents and calcium antihypertensives channel blockers C07FB022 metoprolol and other antihypertensives C07FB02 metoprolol and felodipine3 C07FB13 metoprolol and amlodipine C07FB03 atenolol and other antihypertensives C07FB03 atenolol and nifedipine C07FB07 bisoprolol and other antihypertensives C07FB07 bisoprolol and amlodipine C07FB12 nebivolol and other antihypertensives C07FB12 nevibolol and amlodipine M01AE511 Ibuprofen, combinations N02AJ03 dihydrocodeine and other non-opioid analgesics N02AJ08 codeine and ibuprofen N02AA551 oxycodone, combinations N02AA55 oxycodone and naloxone N02AJ17 oxycodone and paracetamol N02AJ18 oxycodone and acetylsalicylic acid N02AJ19 oxycodone and ibuprofen
N02AA581 dihydrocodeine, combinations N02AJ01 dihydrocodeine and paracetamol N02AJ02 dihydrocodeine and acetylsalicylic acid N02AJ03 dihydrocodeine and other non-opioid analgesics
N02AA591 codeine, combinations excl. N02AJ06 codeine and paracetamol psycholeptics N02AJ07 codeine and acetylsalicylic acid N02AJ08 codeine and ibuprofen N02AJ09 codeine and other non-opioid analgesics
N02AX52 tramadol, combinations N02AJ13 tramadol and paracetamol N02AJ14 tramadol and dexketoprofen N02AJ15 tramadol and other non-opioid analgesics
N02BA511 acetylsalicylic acid, combinations excl. N02AJ02 dihydrocodeine and acetylsalicylic acid psycholeptics N02AJ07 codeine and acetylsalicylic acid N02AJ18 oxycodone and acetylsalicylic acid Previous ATC code and level name New ATC code and/or level name
N02BE511 paracetamol, combinations excl. N02AJ01 dihydrocodeine and paracetamol psycholeptics N02AJ06 codeine and paracetamol N02AJ09 codeine and other non-opioid analgesics N02AJ17 oxycodone and paracetamol
1) Splitting of ATC codes according to contents of the different fixed combinations of opioids and other analgesics. The ATC codes in N02A, N02BA51, N02BE51 and M01AE51 will be maintained for other combinations. Combinations with opioids and non-opioid analgesics currently classified in the following ATC codes N02AA55, N02AA58, N02AA59 will be moved to the new ATC 4th level N02AJ. All the existing combination codes will be kept in N02A since there may be other combinations without analgesics available (e.g. oxycodone and naloxone will remain in N02AA55). The ATC classification of all low dose (<20 mg dose) combinations products of codeine or dihydrocodeine currently classified in N02B or M01A will be altered to the new ATC codes in N02AJ. 2) Splitting of ATC code in connection with alterations in C07FX. 3) Unchanged ATC code, ATC level name changed.
WHO-Oslo, December 2016
ALTERATIONS IN DDDs/ valid from January 2017
ATC code ATC level name Previous DDD New DDD
A16AX01 thioctic acid 0.2 g O,P 0.6 g O,P
B02BD Blood coagulation factors 1 deleted1
G03XB01 mifepristone 0.6 g O 0.2 g O
J01CR01 ampicillin and enzyme inhibitor 2 g2) P 6 g2 P
J02AC04 posaconazole 0.8 g O 0.3 g O
R03BB04 tiotropium bromide 18 mcg3 Inhal.powder 10 mcg3 Inhal.powder
V03AE07 calcium acetate 2 g O 6 g O
1) DDDs for the various blood coagulation factors in all ATC 5th level codes in B02BD are deleted. No new DDDs will be established in B02BD Blood coagulation factors. 2) Refers to ampicillin 3) The DDD for tiotropium bromide is unchanged but has been defined as the content of one inhalation capsule (18 mcg) as tiotropium. Since there are different inhalation capsules on the market containing different amounts of active substance, the DDD is now defined as the delivered dose, which is the same (10 mcg) as tiotropium for all products.
WHO-Oslo, December 2016
NEW ATC CODES valid from January 2017
ATC code ATC level name
A03FA08 cinitapride
A04AD14 rolapitant
A06AH04 naloxone
A07DA06 eluxadoline
A16AA07 metreleptin
A16AX12 trientine
A16AX13 uridine triacetate
B01AF03 edoxaban
B03AB10 ferric maltol
C01BA13 hydroquinidine
C01EB23 tiazotic acid
C07AB14 landiolol
C07FX05 metoprolol and ivabradine
C07FX06 carvedilol and ivabradine
C10AX14 alirocumab
C10BX12 atorvastatin, acetylsalicylic acid and perindopril
D03AX13 Betulae cortex
D11AX23 aminobenzoate potassium
D11AX24 deoxycholic acid
G03GA10 follitropin delta
G04BD13 desfesoterodine
H05BX04 etelcalcetide
J01FA16 solithromycin
J05AF13 tenofovir alafenamide
J05AX68 elbasvir and grazoprevir
J06BB21 bezlotoxumab
L01XC23 elotuzumab
L01XC24 daratumumab
L01XC25 mogamulizumab
L01XC26 inotuzumab ozogamicin
L01XE35 osimertinib
L01XE36 alectinib
L01XE37 rociletinib
L01XE38 cobimetinib
L01XE39 midostaurin
L01XE40 olmutinib
L01XX51 talimogene laherparepvec
L01XX52 venetoclax
L01XX53 vosaroxin
L03AA16 empegfilgrastim
L04AA36 ocrelizumab
L04AA37 baricitinib
L04AC13 ixekizumab
L04AC14 sarilumab
M02AA28 piketoprofen
M05BX05 burosumab
M09AX05 aceneuramic acid
N02AJ14 tramadol and dexketoprofen
N02AJ15 tramadol and other non-opioid analgesics
N04BD03 safinamide
N05AX17 pimavanserin
N05BA24 bentazepam
P01BX02 arterolane and piperaquine
R03AK13 salbutamol and beclometasone
R03AL07 formoterol and glycopyrronium bromide
S01FB51 phenylephrine and ketorolac
V03AE09 patiromer calcium
V04CE03 methacetin (13C) V09IX09 gallium (68Ga) edotreotide
V09IX10 fluoroethyl-L-tyrosine (18F)
V09IX11 fluoroestradiol (18F)
V09IX12 fluciclovine (18F)
WHO-Oslo, December 2016
NEW DDDs valid from January 2017
ATC code ATC level name New DDD
A06AH03 naloxegol 25 mg O
A10AE56 insulin degludec and liraglutide 40 U1) P
A16AB12 elosulfase alfa 20 mg P
A16AB14 sebelipase alfa 5 mg P
B01AC25 cangrelor 50 mg P
B01AF03 edoxaban 60 mg O
B01AX01 defibrotide 1.75 g P
C10AX13 evolocumab 10 mg P
C10AX14 alirocumab 5.4 mg P
G03XB51 mifepristone, combinations 0.2 g 2) O
G04BX163) tiopronin 0.8 g O
J01DI54 ceftolozane and enzyme inhibitor 3 g4) P
J01XA04 dalbavancin 1.5 g5) P
J01XE03 furazidin 0.3 g O
J01XX11 tedizolid 0.2 g O,P
J02AC04 posaconazole 0.3 g P
J02AC05 isavuconazole 0.2 g O,P
J04AB05 rifapentine 0.11 g O
L04AA32 apremilast 60 mg O
L04AC10 secukinumab 10 mg P
M01AE01 ibuprofen 1.2 g P
M09AX03 ataluren 2.8 g O
N03AX23 brivaracetam 0.1 g O,P
N04BD03 safinamide 75 mg O
N05AX14 iloperidone 18 mg O
N05BA24 bentazepam 75 mg O ATC code ATC level name New DDD
N06BX13 idebenone 0.9 g O
R03DA11 doxofylline 0.8 g O,P
R03DX096) mepolizumab 3.6 mg P
V03AE08 ferric citrate 6 g O
1) Refers to insulin degludec 2) Refers to mifepristone 3) ATC code changed from R05CB12, new code valid from January 2017 4) Refers to ceftolozane 5) Course dose 6) ATC code changed from L04AC06, new code valid from January 2017
WHO-Oslo, December 2016